{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:54:25Z","timestamp":1793822065246,"version":"4.6.1"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"Supplement_6","funder":[{"name":"Seres and Ferring"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The profound impact of the human microbiome on health and disease has captivated the interest of clinical and scientific communities. The human body hosts a vast array of microorganisms collectively forming the human microbiome, which significantly influences various physiological processes and profoundly shapes overall well-being. Notably, the gut stands out as an exceptional reservoir, harboring the most significant concentration of microorganisms, akin to an organ in itself. The gut microbiome's composition and function are influenced by genetics, environment, age, underlying conditions, and antibiotic usage, leading to dysbiosis and pathogenesis, such as Clostridioides difficile infection (CDI). Conventional CDI treatment, involving antibiotics like oral vancomycin and fidaxomicin, fails to address dysbiosis and may further disrupt gut microbial communities. Consequently, emerging therapeutic strategies are focused on targeting dysbiosis and restoring gut microbiota to advance CDI therapeutics. Fecal microbiota transplantation (FMT) has demonstrated remarkable efficacy in treating recurrent CDI by transferring processed stool from a healthy donor to a recipient, restoring gut dysbiosis and enhancing bacterial diversity. Moreover, 2 newer Food and Drug Administration (FDA)-approved live biotherapeutic products (LBP), namely, Fecal Microbiota Live-JSLM and Fecal Microbiota Spores Live-BRPK, have shown promise in preventing CDI recurrence. This review explores the role of the gut microbiota in preventing and treating CDI, with an emphasis on gut-based interventions like FMT and fecal microbiota-based products that hold potential for gut restoration and prevention of CDI recurrence. Understanding the microbiome's impact on CDI prevention and treatment offers valuable insights for advancing future CDI therapeutics.<\/jats:p>","DOI":"10.1093\/cid\/ciad639","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T20:37:54Z","timestamp":1701808674000},"page":"S447-S454","source":"Crossref","is-referenced-by-count":16,"title":["Advancements in Novel Live Biotherapeutic Products for <i>Clostridioides difficile<\/i> Infection Prevention"],"prefix":"10.1093","volume":"77","author":[{"given":"Thomas","family":"Lavoie","sequence":"first","affiliation":[{"name":"Infectious Diseases Research Program, Providence Veterans Affairs Medical Center , Providence, Rhode Island , USA"},{"name":"College of Pharmacy, University of Rhode Island , Kingston, Rhode Island , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley J","family":"Appaneal","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Program, Providence Veterans Affairs Medical Center , Providence, Rhode Island , USA"},{"name":"Center of Innovation in Long-Term Support Services, Providence Veterans Affairs Medical Center , Providence, Rhode Island , USA"},{"name":"College of Pharmacy, University of Rhode Island , Kingston, Rhode Island , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9650-4275","authenticated-orcid":false,"given":"Kerry L","family":"LaPlante","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Program, Providence Veterans Affairs Medical Center , Providence, Rhode Island , USA"},{"name":"College of Pharmacy, University of Rhode Island , Kingston, Rhode Island , USA"},{"name":"Center of Innovation in Long-Term Support Services, Providence Veterans Affairs Medical Center , Providence, Rhode Island , USA"},{"name":"Warren Alpert Medical School of Brown University , Division of Infectious Diseases, Providence, Rhode Island , USA"},{"name":"School of Public Health, Brown University , Providence, Rhode Island , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"2023121213592737700_ciad639-B1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41385-022-00564-1","article-title":"Microbiome-based interventions to modulate gut ecology and the immune system","volume":"15","author":"Hitch","year":"2022","journal-title":"Mucosal Immunol"},{"key":"2023121213592737700_ciad639-B2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaci.2017.05.015","article-title":"An exposome perspective: early-life events and immune development in a changing world","volume":"140","author":"Renz","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2023121213592737700_ciad639-B3","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1172\/JCI72336","article-title":"Clostridium difficile and the microbiota","volume":"124","author":"Seekatz","year":"2014","journal-title":"J Clin Invest"},{"key":"2023121213592737700_ciad639-B4","doi-asserted-by":"crossref","first-page":"17562848221134396","DOI":"10.1177\/17562848221134396","article-title":"The role of the gut microbiome in colonization resistance and recurrent","volume":"15","author":"Seekatz","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"2023121213592737700_ciad639-B5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/toxins8050134","article-title":"Clostridium difficile toxins A and B: insights into pathogenic properties and extraintestinal effects","volume":"8","author":"Di Bella","year":"2016","journal-title":"Toxins (Basel)"},{"key":"2023121213592737700_ciad639-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5009\/gnl.2014.8.1.1","article-title":"Clostridium difficile infection: a worldwide disease","volume":"8","author":"Burke","year":"2014","journal-title":"Gut Liver"},{"key":"2023121213592737700_ciad639-B7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1086\/525047","article-title":"Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea","volume":"197","author":"Chang","year":"2008","journal-title":"J Infect Dis"},{"key":"2023121213592737700_ciad639-B8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1128\/JCM.05176-11","article-title":"Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota","volume":"50","author":"Rea","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2023121213592737700_ciad639-B9","doi-asserted-by":"crossref","first-page":"010417","DOI":"10.7189\/jogh.07.010417","article-title":"Risk factors for Clostridium difficile infections\u2014an overview of the evidence base and challenges in data synthesis","volume":"7","author":"Eze","year":"2017","journal-title":"J Glob Health"},{"key":"2023121213592737700_ciad639-B10","doi-asserted-by":"crossref","first-page":"e1260","DOI":"10.1002\/mbo3.1260","article-title":"Impact of antibiotics on the human microbiome and consequences for host health","volume":"11","author":"Patangia","year":"2022","journal-title":"Microbiologyopen"},{"key":"2023121213592737700_ciad639-B11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/00365540802651897","article-title":"Prolonged impact of a one-week course of clindamycin on Enterococcus spp. in human normal microbiota","volume":"41","author":"Lindgren","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"2023121213592737700_ciad639-B12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40168-020-00875-0","article-title":"Microbiome definition re-visited: old concepts and new challenges","volume":"8","author":"Berg","year":"2020","journal-title":"Microbiome"},{"key":"2023121213592737700_ciad639-B13","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/nu14071527","article-title":"Fermented foods, health and the gut microbiome","volume":"14","author":"Leeuwendaal","year":"2022","journal-title":"Nutrients"},{"issue":"Suppl 2","key":"2023121213592737700_ciad639-B14","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1086\/523339","article-title":"Probiotics in the United States","volume":"46","author":"Vanderhoof","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023121213592737700_ciad639-B15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1756283X12459294","article-title":"Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation","volume":"6","author":"Hemarajata","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"2023121213592737700_ciad639-B16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/fmb-2021-0206","article-title":"Effect of prebiotics on Bacteroides sp. adhesion and biofilm formation and synbiotic effect on Clostridioides difficile","volume":"17","author":"Piotrowski","year":"2022","journal-title":"Future Microbiol"},{"key":"2023121213592737700_ciad639-B17","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1136\/gutjnl-2015-309957","article-title":"High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome","volume":"65","author":"De Filippis","year":"2016","journal-title":"Gut"},{"key":"2023121213592737700_ciad639-B18","first-page":"CD004611","article-title":"Probiotics for treatment of Clostridium difficile-associated colitis in adults","volume":"1","author":"Pillai","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2023121213592737700_ciad639-B19","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1001\/jama.2012.3507","article-title":"Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis","volume":"307","author":"Hempel","year":"2012","journal-title":"JAMA"},{"key":"2023121213592737700_ciad639-B20","doi-asserted-by":"crossref","first-page":"e34938","DOI":"10.1371\/journal.pone.0034938","article-title":"A meta-analysis of probiotic efficacy for gastrointestinal diseases","volume":"7","author":"Ritchie","year":"2012","journal-title":"PLoS One"},{"key":"2023121213592737700_ciad639-B21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG Clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2023121213592737700_ciad639-B22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/apt.17049","article-title":"Review article: the future of microbiome-based therapeutics","volume":"56","author":"Gulliver","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2023121213592737700_ciad639-B23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40121-018-0189-y","article-title":"Comparison of different strategies for providing fecal microbiota transplantation to treat patients with recurrent Clostridium difficile infection in two English hospitals: a review","volume":"7","author":"Goldenberg","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2023121213592737700_ciad639-B24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/apt.14201","article-title":"Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection","volume":"46","author":"Quraishi","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2023121213592737700_ciad639-B25","doi-asserted-by":"crossref","first-page":"100642","DOI":"10.1016\/j.eclinm.2020.100642","article-title":"Faecal microbiota transplantation for recurrent","volume":"29\u201330","author":"Baunwall","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2023121213592737700_ciad639-B26","doi-asserted-by":"crossref","first-page":"e0161174","DOI":"10.1371\/journal.pone.0161174","article-title":"Systematic review: adverse events of fecal microbiota transplantation","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"2023121213592737700_ciad639-B27","doi-asserted-by":"crossref","first-page":"100069","DOI":"10.1016\/j.infpip.2020.100069","article-title":"Regulation, risk and safety of faecal microbiota transplant","volume":"2","author":"Merrick","year":"2020","journal-title":"Infect Prev Pract"},{"key":"2023121213592737700_ciad639-B28","first-page":"150","article-title":"Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis","volume":"35","author":"Rapoport","year":"2022","journal-title":"Ann Gastroenterol"},{"key":"2023121213592737700_ciad639-B29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2022.03.051","article-title":"Effectiveness and safety of fecal microbiota transplantation for Clostridioides difficile infection: results from a 5344-patient cohort study","volume":"163","author":"Osman","year":"2022","journal-title":"Gastroenterology"},{"key":"2023121213592737700_ciad639-B30","volume-title":"REBYOTA [Package insert]","year":"2022"},{"key":"2023121213592737700_ciad639-B31","volume-title":"VOWST [Package insert]","year":"2023"},{"key":"2023121213592737700_ciad639-B32","doi-asserted-by":"crossref","first-page":"e876","DOI":"10.1093\/cid\/ciaa1486","article-title":"Shiga toxin-producing Escherichia coli transmission via fecal microbiota transplant","volume":"72","author":"Zellmer","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023121213592737700_ciad639-B33","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"key":"2023121213592737700_ciad639-B34","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/ajg.2013.164","article-title":"Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts","volume":"108","author":"Schwartz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2023121213592737700_ciad639-B35","author":"US FDA","year":"2020"},{"key":"2023121213592737700_ciad639-B36","author":"US FDA","year":"2019"},{"key":"2023121213592737700_ciad639-B37","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jama.2023.4314","article-title":"VE303, A defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial","volume":"329","author":"Louie","year":"2023","journal-title":"JAMA"},{"key":"2023121213592737700_ciad639-B38","doi-asserted-by":"crossref","first-page":"17562848231174277","DOI":"10.1177\/17562848231174277","article-title":"Safety of fecal microbiota, live-jslm (REBYOTA(\u2122)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials","volume":"16","author":"Lee","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"2023121213592737700_ciad639-B39","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","article-title":"Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection","volume":"82","author":"Khanna","year":"2022","journal-title":"Drugs"},{"key":"2023121213592737700_ciad639-B40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40121-022-00744-3","article-title":"Final results from a phase 2b randomized, placebo-controlled clinical trial of RBX2660: a microbiota-based drug for the prevention of recurrent Clostridioides difficile infection","volume":"12","author":"Dubberke","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2023121213592737700_ciad639-B41","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12879-022-07256-y","article-title":"Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial","volume":"22","author":"Orenstein","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2023121213592737700_ciad639-B42","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N Engl J Med"},{"key":"2023121213592737700_ciad639-B43","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1001\/jama.2022.16476","article-title":"Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection in a randomized clinical trial","volume":"328","author":"Cohen","year":"2022","journal-title":"JAMA"},{"key":"2023121213592737700_ciad639-B44","doi-asserted-by":"crossref","first-page":"e2255758","DOI":"10.1001\/jamanetworkopen.2022.55758","article-title":"Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial","volume":"6","author":"Sims","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2023121213592737700_ciad639-B45","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1093\/cid\/ciaa387","article-title":"SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial","volume":"72","author":"McGovern","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023121213592737700_ciad639-B46","doi-asserted-by":"crossref","first-page":"e2253570","DOI":"10.1001\/jamanetworkopen.2022.53570","article-title":"Assessment of quality of life among patients with recurrent Clostridioides difficile infection treated with investigational oral microbiome therapeutic SER-109: secondary analysis of a randomized clinical trial","volume":"6","author":"Garey","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2023121213592737700_ciad639-B47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41687-020-0179-1","article-title":"Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey","volume":"4","author":"Lurienne","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2023121213592737700_ciad639-B48","doi-asserted-by":"crossref","first-page":"ofw133","DOI":"10.1093\/ofid\/ofw133","article-title":"Clearance of vancomycin-resistant enterococcus concomitant with administration of a microbiota-based drug targeted at recurrent Clostridium difficile infection","volume":"3","author":"Dubberke","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2023121213592737700_ciad639-B49","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3390\/antibiotics11091234","article-title":"SER-109: an oral investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infection (rCDI)","volume":"11","author":"Khanna","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2023121213592737700_ciad639-B50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s40168-020-00907-9","article-title":"Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial","volume":"8","author":"Kwak","year":"2020","journal-title":"Microbiome"},{"key":"2023121213592737700_ciad639-B51","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/pathogens11060642","article-title":"Manipulating microbiota to treat atopic dermatitis: functions and therapies","volume":"11","author":"Alam","year":"2022","journal-title":"Pathogens"},{"key":"2023121213592737700_ciad639-B52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12967-022-03365-z","article-title":"Irritable bowel syndrome and microbiome; switching from conventional diagnosis and therapies to personalized interventions","volume":"20","author":"Ghaffari","year":"2022","journal-title":"J Transl Med"},{"key":"2023121213592737700_ciad639-B53","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/infdis\/jiv766","article-title":"A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection","volume":"214","author":"Khanna","year":"2016","journal-title":"J Infect Dis"},{"key":"2023121213592737700_ciad639-B54","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/cid\/civ938","article-title":"Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study","volume":"62","author":"Orenstein","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023121213592737700_ciad639-B55","doi-asserted-by":"crossref","first-page":"ofac448","DOI":"10.1093\/ofid\/ofac448","article-title":"Manufacturing process of SER-109, a purified investigational microbiome therapeutic, reduces risk of coronavirus transmission from donor stool","volume":"9","author":"McChalicher","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023121213592737700_ciad639-B56","volume-title":"Product information: DIFICID(R) oral tablets, oral suspension, fidaxomicin oral tablets, oral suspension","year":"2020"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_6\/S447\/54335127\/ciad639.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_6\/S447\/54335127\/ciad639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T17:56:57Z","timestamp":1702403817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/Supplement_6\/S447\/7459145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":56,"journal-issue":{"issue":"Supplement_6","published-online":{"date-parts":[[2023,12,5]]},"published-print":{"date-parts":[[2023,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad639","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,12,1]]}}}